Related Experiment Videos
Towards gene therapy for hemophilia B
Molecular Biology & Medicine
|February 1, 1987
Summary
Gene therapy offers a promising alternative for hemophilia B. Human skin cells can be engineered to produce active clotting factor IX, potentially revolutionizing treatment for this bleeding disorder.
Area of Science:
- Medical Genetics
- Hematology
- Gene Therapy
Background:
- Hemophilia B is a genetic bleeding disorder caused by deficient clotting factor IX.
- Current treatments involve plasma-derived factor IX, posing risks of viral contamination and logistical challenges.
Purpose of the Study:
- To explore gene therapy as an alternative treatment for hemophilia B.
- To assess the feasibility of using somatic cells for sustained factor IX production.
Main Methods:
- Construction of a retrovirus vector for factor IX gene transfer.
- Transduction of human skin-derived fibroblasts to express factor IX.
Main Results:
- Fully active factor IX was successfully produced by engineered human skin fibroblasts.
- Demonstrated that fibroblasts can perform necessary post-translational modifications for factor IX activity.
Conclusions:
- Human skin fibroblasts are a viable cell source for gene therapy of hemophilia B.
- Skin grafts engineered for factor IX production represent a potential new therapeutic strategy.